CNR1 and type 2 diabetes mellitus: Endocannabinoids, and particularly CB1, have been shown to play an important role in metabolic disease such as fatty liver disease, type II diabetes, diet-induced steatosis, and dyslipidemia and are generally associated with overactivity [117,118,119,120,121,122].